10. Шерлок ILL, Дули Дж. Заболевания печени и желчных путей: практическое руководство / Пер. с англ. / Под ред. Апросиной З.Г., Мухина Н.А. — М.: Гэотар Медицина, 1999. — 864 с.
11. Musso G., Gambino R., Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update // Obesity Reviews. — 2010. — № 11(6). — P. 430–45.
12. McPherson S., Hardy T., Henderson E. et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management //J. Hepatol. 2015. Vol. 62. № 5. P. 1148–1155.
13. Musso G., Gambino R., Cassader M., Pagano G.F., (2011). Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43: 617–649.
14. Benedict M., Zhang X.. Non-alcoholic fatty liver disease: An expanded review. World Journal of Hepatology. 2017;9(16):715–732. doi:10.4254/wjh.v9.il6.715.
15. Lazo M., Clark J. The epidemiology of nonalcoholic fatty liver disease: a global perspective // Semin Liver Dis. -2008.-№ 28(4). — P. 339–50.
16. Doycheva, Cui J., Nguyen P. et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Alimentary Pharmacology & Therapeutics, January 2016, Volume 43, Issue 1, pages 83–95.
17. Lonardo A., Bellentani S., Argo C.K. et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis. 2015; 47(12):997-1006. doi: 10.1016/j.dld.2015.08.004.
18.
Ballestri S.,Nascimbeni F., Baldelli E. et al. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. Adv. Ther. 2017; 34(6): 1291–1326. Published online 2017 May 19. doi: 10.1007/S12325-017-0556-1.19. Sookoian S., Pirola C.J. Genetic predisposition in nonalcoholic fatty liver disease. Clinical and Molecular Hepatology. 2017;23(1):1-12. doi:10.3350/cmh.2016.0109.
20. Caligiuri A., Gentilini A., Marra F. Molecular Pathogenesis of NASH. International Journal of Molecular Sciences. 2016;17(9):1575. doi:10.3390/ijmsl7091575.
21. Green C J., Hodson L. The Influence of Dietary Fat on Liver Fat Accumulation. Nutrients. 2014;6(ll):5018–5033. doi:10.3390/nu6115018.
22. Ferramosca A., Zara V. Modulation of hepatic steatosis by dietary fatty acids. World Journal of Gastroenterology: WJG. 2014;20(7):1746–1755. doi:10.3748/wjg.v20.i7.1746.
23. Chakraborty S. Analysis of NHANES 1999–2002 data reveals noteworthy association of alcohol consumption with obesity. Ann Gastroenterol. 2014;27(3):250-257
24. Zakhari S., Li T.K. Determinants of alcohol use and abuse: impact of quantity and frequency patterns on liver disease. Hepatology, 2007;46:2032–2039.
25. Rutkowski J.M., Stern J.H., Scherer P.E. The cell biology of fat expansion. J Cell Biol Mar 2015,208 (5) 501–512; DOI: 10.1083/jcb.201409063.
26. Schaffer J.E. Lipotoxicity: Many Roads to Cell Dysfunction and Cell Death: Introduction to a Thematic Review Series. Journal of Lipid Research. 2016;57(8):1327–1328. doi:10.1194/jlr.E069880.
27. Byrne C.D. Dorothy Hodgkin Lecture 2012: nonalcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabet Med. 29(9):1098-107.
28. Tsochatzis E.A. Adipokines in Nonalcoholic Steato-hepatitis: From Pathogenesis to Implications in Diagnosis and Therapy. Mediators Inflamm. 2009: 831670.
29. Lonardo A., Sookoian S., Chonchol M.et al. Cardiovascular and systemic risk in nonalcoholic fatty liver disease — atherosclerosis as a major player in the natural course of NAFLD. Curr Pharm Des. 2013;19(29):5177-92.
30. Wende A.R., Symons J.D., Abel E.D. Mechanisms of Lipotoxicity in the Cardiovascular System. Current hypertension reports. 2012;14(6):517–531. doi:10.1007/sll906-012-0307.
31. Marchesini G., Bugianesi E., Forlani G. et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003 Apr;37(4):917-23.
32. Min H.K. et al. Increased hepatic synthesis and dysrégulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 2012 May 2;15(5):665-74.
33. Brown M.S., Goldstein J.L. Nobel lecture, 9 December, 1985.
34. Fuchs M. et al. Gastroenterology, 2012; Vol. 142, Issue 5, S-1015.
35. Musso G., Gambino R., Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res. 2013 Jan;52(l):175-91. doi: 10.1016/j. plipres.2012.11.002. Epub 2012 Dec 1.
36. Вовк Е.И. Неалкогольная жировая болезнь печени: от научных достижений к клиническим алгоритмам. Медицинский совет; 2013; № 10; http://dx.doi. org/10.21518/2079-701X-2013-10-46-51.